WHO Expert Committee on Biological Standardization: highlights of the 50th meeting, October 1999
Related Experiment Video
Updated: Oct 13, 2026
Reproducibility and Harmonization in Research Using Biological Standards: The Example of Platelet Agonist Collagen-Related Peptide
Published on: August 4, 2023
D J Wood1, A Padilla, E Griffiths
1Division of Virology, National Institute of Biological Standards and Controls, South Mimms, Potters Bar, Herts, EN6 3QG, UK.
Abstract:
Biological medicines, which include vaccines, blood products and biological therapeutics, have historically played a dominant role in improving world health and are expected to make an increasingly important contribution to public health in the 21st century. Recent scientific and biotechnological developments have opened the way to novel products, new production methods and to highly sensitive assay procedures. However, the nature of biologicals, and especially new vaccines, blood products and therapeutics, raises particular questions regarding their standardization and quality control. These relate both to efficacy and to safety not only for the individual recipient but also for the population at large. Such advances highlight the complex issues surrounding standardization and control of biologicals, issues that need to be addressed on an international level.